Physician profile
Caleb I Moore
NPI 1366461790
$4,437.66
in general payments reported to CMS, 2019-2025
28 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $2,130 · 2021: $144 · 2022: $342 · 2023: $897 · 2024: $510 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,564.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Butterfly Network, INC. | $2,028.00 | 2020 | |
| Abbvie INC. | $582.70 | 2021-2025 | |
| Pfizer INC. | $353.68 | 2021-2025 | |
| Novo Nordisk INC | $318.59 | 2020-2024 | Wegovy, Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.92 | 2019-2024 | Xifaxan |
| Exact Sciences Corporation | $121.80 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Eisai INC. | $120.57 | 2024 | |
| Glaxosmithkline, LLC. | $99.24 | 2019-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $98.93 | 2019-2024 | Breztri |
| Merck Sharp & Dohme LLC | $75.15 | 2019-2025 | Gardasil 9, Capvaxive, Pneumovax 23 |
| Lilly USA, LLC | $63.40 | 2024 | Amyvid, Kisunla |
| Kowa Pharmaceuticals America, INC. | $51.76 | 2019-2021 | |
| Sanofi Pasteur INC. | $41.75 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $32.50 | 2019-2020 | |
| Csl Behring | $30.47 | 2024 | Haegarda |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $29.34 | 2019-2020 | |
| Horizon Therapeutics Plc | $26.37 | 2023 | Krystexxa |
| Amarin Pharma, INC. | $26.27 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $25.25 | 2023 | Eliquis |
| Halozyme INC | $23.44 | 2023 | |
| Astellas Pharma US INC | $21.59 | 2019 | |
| Seqirus USA INC | $21.22 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.26 | 2019 | |
| Cleerly, INC. | $19.02 | 2023 | Cleerly Labs |
| Amgen INC. | $16.40 | 2024 | Enbrel |
| Phadia US INC. | $15.00 | 2023 | Immunocap |
| Medtronic USA, INC. | $14.64 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.